Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

Healthcare utilization and costs among relapsed or refractory multiple myeloma patients on carfilzomib or pomalidomide as monotherapy or in combination with dexamethasone

搜集汇总

背景与挑战

背景概述

该数据集研究了复发或难治性多发性骨髓瘤患者的医疗资源使用情况和成本，这些患者接受了卡非佐米或泊马度胺作为单药治疗，或与地塞米松联合治疗。